Occuity, a British MedTech company that primarily focuses on non-contact optical devices, is currently in the research and development phase and has raised £2.85 million in investment for its non-contact optical glucose meter called the Occuity Indigo. The company have also mentioned that the device could be used in optical practices, pharmacies, or domiciliary settings in the future.
The technology is centred on the company’s optical confocal scanning technology and the Occuity Indigo device is constructed to assist patients with diabetes in monitoring their blood-sugar levels by scanning the eyes.
Occuity has hinted that the technology caught the interest of investors for its extensive potential applications for conditions including glaucoma, myopia, diabetes management, and pre-diabetes screening. There is also the possibility that this new technology could eventually be used in the early detection of Alzheimer’s disease.
Daniele De Iuliis at Occuity has commented on the Occuity Indigo device: “For too long now, the way in which we discover and monitor chronic diseases like diabetes has been routed in repetitive finger stick blood testing with all the pain, discomfort and inconvenience that brings. In contrast, the Occuity Indigo will be a discrete handheld product that will simply scan the eye to take a glucose measurement providing a pain-free 21st century solution that is long overdue.”